Apollo Hospitals Group chooses Elekta’s MOSAIQ for new proton center
NEW DELHI, May 4, 2018 – Elekta (EKTA-B.ST) announced today that Asia’s foremost integrated healthcare services provider, Apollo Hospitals, has chosen Elekta's vendor-neutral, open source MOSAIQ® oncology information system for its Apollo Proton Cancer Centre (APCC) in Chennai, India. The proton therapy solution is being provided by IBA (Ion Beam Applications).
Apollo Hospitals expects that this first proton therapy center in South Asia will provide access to this technology to more than three billion people.
Ranjit Pradhan, Senior Vice President Portfolio & Business Development Software Solutions at Elekta, said: “A key aspect in Apollo Hospitals choice of Elekta is interoperability. Our collaboration with IBA and Equicare is just one example of how we are building a strong network of key ‘best of breed’ vendors as part of our partnerships and open connectivity.”
In addition to IBA’s three Proton Rooms, all with IMPT’s MOSAIQ, will be used together with the hospital’s Accuray Radixact and Varian TrueBeam treatment delivery systems. The deal includes licenses to run Elekta’s MOSAIQ® Medical Oncology system in the same database.
Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Group said: “The Apollo Group is at the forefront of leveraging technologies that improve patient care and create efficient workflows for clinicians to seamlessly deliver healthcare of high quality. Today, our hospitals are amongst the first to introduce filmless and paperless technology that deliver care through fully integrated electronic medical records and hospital information systems. Elekta’s collaboration with IBM Watson Health to unite its ‘Watson for Oncology’ computing technology with Elekta’s portfolio of digital solutions was a key factor that influenced our decision to choose Elekta.
“With Elekta’s MOSAIQ® oncology information system at APCC, we aspire to provide the most advanced, comprehensive and efficient care management for radiation, medical and surgical oncology to our patients. We are planning to commence our proton therapy unit by September this year.”
In 2017, Elekta and IBA announced that they would co-invest in developing new functionality for proton therapy treatment in Elekta’s Monaco® treatment planning system and MOSAIQ oncology information system. The purpose is to offer a more seamless experience for comprehensive radiotherapy departments and further improve patient care.
Elekta and Equicare Health established a reseller agreement in January 2018 to enhance cancer patient engagement, care and management. Through this agreement, patients can receive updates on their care plans, provide feedback and patient reported outcomes through the platform. Clinical information is integrated into MOSAIQ directly from Equicare CS™.
# # #
For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Media Relations
Tel: +1 770 670 2447, e-mail: email@example.com
Time zone: ET: Eastern Time
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm.